⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30876844 | 1.00 | — | — | |
| SCHEMBL28504864 | 0.97 | CDK2 (0.95) | — | |
| SCHEMBL138054 | 0.78 | — | — | |
| SCHEMBL1604498 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL31108165 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL31108166 | 0.76 | — | — | |
| Formamide SCHEMBL28506642 | 0.70 | CDK2 (0.54) | — | |
| SCHEMBL6658388 | 0.67 | — | — | |
| SCHEMBL22561740 | 0.67 | — | — | |
| SCHEMBL5751670 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112724089-B | Synthesis process of 2-amino-3-bromo-6-chloropyrazine | 烟台皓元生物医药科技有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-111217760-B | Synthetic method of sulfachloropyrazine sodium | 湖南吴赣药业有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-112724089-A | Synthesis process of 2-amino-3-bromo-6-chloropyrazine | 烟台共进医药科技有限公司 | 2021-04-30 | — | — | CN | claimed |
| CN-111217760-A | Synthetic method of sulfachloropyrazine sodium | 湖南吴赣药业有限公司 | 2020-06-02 | — | — | CN | claimed |
| CN-107857737-A | A kind of preparation technology of the chloropyrazine of 2 bromine 3,5,6 3 | 贵州大学 | 2018-03-30 | — | — | CN | claimed |
| CN-103865290-B | Fluorine boron fluorescence dye and its preparation method and application | ANHUI NORMAL UNIVERSITY (CN) | 2016-03-30 | — | — | CN | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| EP-0267675-A2 | Modified conjugated diene polymer and process for production thereof | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1988-05-18 | — | — | EP | claimed |
| EP-0106214-B1 | 4-HYDROXY-2H-1,2-BENZOTHIAZINE-3-CARBOXAMIDE-1,1-DIOXIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AND THERAPEUTIC AGENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1985-12-04 | — | — | EP | claimed |
| EP-0106214-A1 | 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides, process for their preparation, their use and therapeutic agents containing them | Dr. Karl Thomae GmbH (DE) | 1984-04-25 | — | — | EP | claimed |